Trastuzumab emtansine

Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech’s trastuzumab antibody linked to ImmunoGen’s cell-killing agent, DM1. T-DM1 combines two strategies– anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)–to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated in use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects including hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. It is grouped under the following drug class(es): Antineoplastic agents and Monoclonal antibodies. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Trastuzumabum emtansinum, Ado-trastuzumab emtansine and Kadcyla. Its PubChem SID is 483928192.

CAS No 1018448-65-1
Molecular Formula C6448H9948N1720O2012S44
Molecular Weight 148,500 g/mol
Synonyms N/A

Frequently Asked Questions